Philips and BG Medicine Form Alliance for Molecular Medicine Research and Development

Partners to embark upon joint development of molecular imaging and diagnostic
products

Waltham, MA – Royal Philips Electronics (NYSE: PHG, AEX: PHI) and BG Medicine
have established an alliance in the field of Systems Biology. Under the partnership
agreement BG Medicine will collaborate with Philips to develop the next generation of
molecular healthcare products for application in areas such as molecular imaging and
point-of-care diagnostics. Key to the alliance is BGM’s proprietary systems profiling
technologies that identify biomarker sets associated with disease stage, progression and
treatment. BG Medicine has granted Philips preferential access to certain of its
proprietary technologies and services, and Philips has acquired a minority stake in BG
Medicine, which is privately-held and based in Waltham, Massachusetts.

“We are at the dawn of a new era in medicine where technology and biology are applied
in conjunc tion to create a whole new generation of approaches to diagnosis and treatment
with improved clinical outcomes,” said Rick Harwig, CTO of Philips. “The Philips-BG
Medicine partnership brings together the important capabilities and resources that are
required to execute our healthcare vision and strategy.”

“The convergence of technology and biology creates exciting new opportunities in
healthcare,” said Pieter Muntendam, MD, President and CEO of BG Medicine. “The
partnership announced today between Philips and BG Medicine provides a strategic
foundation and framework for a series of joint initiatives in molecular medicine focused
on important areas such as cardiovascular disease and oncology.”

The advancement of molecular medicine through Systems Biology promises to
revolutionize the practice of healthcare by allowing earlier detection of disease and drug
response, thereby increasing the effectiveness of treatment and minimizing the severity or
duration of an illness. Molecular medicine is also a keystone in developing individualized
therapeutic treatments and diagnostics for improved patient outcomes.

About BG Medicine

BG Medicine, founded in 2000, is a pioneer in the commercial application of Systems
Biology. The founding investors are Flagship Ventures (Cambridge, MA) and Gilde
Investment Management (Utrecht, Netherlands). BG Medicine’s proprietary approaches
integrate multiple bioanalytical platforms such as proteomics and metabolomics with
powerful bioinformatics and computational analysis. This approach enables the
discovery and qualification of accessible biomarkers that form the basis for advanced
diagnostics, and provides key insights into disease and drug response. Applied to
pharmaceutical development, these approaches can shorten drug development timelines
and reduce attrition of drug candidates in late stage trials. BG Medicine’s portfolio of
projects includes partnerships with a number of leading organizations, such as
AstraZeneca, Boehringer Ingelheim, Elan, GlaxoSmithKline, Mitsubishi Pharma,
Novartis, TB Alliance, and the FDA. For more information about BG Medicine please
visit www.bg-medicine.com.

Contact: A. Stacie Rader
Corporate Communications
781-434-0287
srader@bg-medicine.com

Return to News